Trial results
$TECX — TX45
Tectonic Therapeutic, Inc. (TECX) TX45: trial results in Pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), 2027.
The catalyst
"Topline results from the APEX Phase 2 clinical trial of TX45 in pulmonary hypertension associated with heart failure with preserved ejection fraction ("PH-HFpEF") are anticipated by the end of January 2027"
— Tectonic Therapeutic, 8-K filed 2026-11-05 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.
- Event id
TECX-TX45-2026- Company
- Tectonic Therapeutic, Inc.
- Kind
- Trial results
- Indication
- Pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF)
- Window
- 2027-01-01 – 2027-01-31
- Status
- dropped
The bar
No bar has been published for this event yet.
Verdicts
No verdict has been published for this event yet.